Menarini to enhance BPDCN detection with VisualDx’s link
The Menarini Group, along with its subsidiary Stemline Therapeutics, has announced a partnership with VisualDx to enhance the ...
Le Lézard1d
Copia Wealth Studios Unveils "Clarity" - AI-Powered Wealth Management Platform for Sophisticated Investors
Copia Wealth Studios today announced the launch of "Copia - Clarity," an advanced wealth management platform designed specifically for sophisticated allocators managing diverse investment portfolios.
Menarini Group Announces Collaboration with VisualDx to Aid in Identifying People...
The Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc.
The Manila Times2d
Star Equity Holdings, Inc. Announces 2024 Fourth Quarter and Full Year Financial Results
Star Equity Holdings, Inc. is a diversified holding company with three divisions: Building Solutions, Energy Services, and ...
Targeted Oncology4d
The Role of CD123 Targeted Therapy (tagraxofusp) in the Evolving Treatment Landscape for BPDCN
An expert discusses how medical professionals have integrated tagraxofusp into blastic plasmacytoid dendritic cell neoplasm (BPDCN) treatment, leveraging its CD123-targeted efficacy per 0114 trial ...
Targeted Oncology4d
An Overview of Treatment Approaches for BPDCN
An expert discusses how, historically, blastic plasmacytoid dendritic cell neoplasm (BPDCN) was treated with regimens for acute leukemia or lymphoma. Current NCCN guidelines recommend intensive ...